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Abstract
Introduction
Infection with human papillomavirus (HPV) is common and can
progress to various types of cancer. HPV infection can be preven-
ted through vaccination; however, vaccination rates among adoles-
cents are low. The objective of this study was to assess efforts
among Wisconsin stakeholders in HPV vaccination and organiza-
tional capacity for future collaborative work.
Methods
We conducted a cross-sectional online survey of 277 stakeholders
in HPV vaccination activities, from April 30, 2015, through June
30, 2015. Stakeholders were public health professionals, health
care providers, educators, quality improvement professionals, re-
searchers, and advocates identified as engaged in HPV vaccina-
tion work.
Results
Of the 277 invited stakeholders, 117 (42%) responded to the sur-
vey. Findings showed that most current HPV vaccination activit-
ies targeted 3 groups: adolescents and parents, clinical and health
professionals,  and communities  and health systems.  The main
activities directed at these groups were providing printed educa-
tional materials, professional education, and media campaigns to
raise awareness. Common barriers reported were lack of under-
standing about the link between HPV and cancer, requests to delay
vaccination, difficulty completing the 3-dose vaccine series, and
reluctance to discuss sexuality.
Conclusion
HPV vaccination rates are far below those of other vaccinations
administered to adolescents in Wisconsin. Our study showed that
various local efforts were being made to increase HPV vaccina-
tion uptake; however, many barriers exist to initiation and comple-
tion of the vaccine series. Future interventions should address bar-
riers and employ evidence-based strategies for increasing HPV
vaccination rates.
Introduction
Human papillomavirus (HPV) infection is common, especially
among young adults (1–3). Almost all cervical and anal cancers
and most oropharyngeal cancers are caused by persistent infection
with high-risk HPV, types 16 and 18 (4–6). HPV vaccines offer
the best protection to women and men who receive all 3 doses in
the series and have time to develop an immune response before
becoming sexually active. Initiation of HPV vaccination is recom-
mended for girls and boys beginning when they are aged 11 to 12
years (6). It is also recommended for girls aged 13 to 26 and for
boys aged 13 to 21 who have not been vaccinated (7–9). However,
since licensure of the first HPV vaccine in 2006, vaccination rates
have remained low in the United States compared with rates for
other adolescent vaccinations. In Wisconsin, data from the Wis-
consin Immunization Registry indicate that HPV vaccination cov-
erage is far lower than for other vaccines administered to adoles-
cents. In 2013, an estimated 55% of girls and 29% of boys aged 13
to 17 had initiated the HPV vaccine series, and only 34% of girls
and 11% of boys aged 13 to 17 had completed the series. By com-
parison, 92% of adolescents in this age group have received the
tetanus,  diphtheria,  pertussis (Tdap) vaccine,  and 75% had re-
ceived the meningococcal conjugate vaccine (10).
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The Wisconsin Comprehensive Cancer Control Program, housed
at  the  University  of  Wisconsin  Carbone  Cancer  Center,  was
among 18 sites funded by the National Cancer Institute to conduct
an environmental scan of HPV vaccination activities to enhance
collaborations for developing research and interventions to in-
crease HPV vaccination rates in Wisconsin (11).  The scan in-
volved 4 components: 1) examination of vaccination data from the
Wisconsin Immunization Registry, 2) a survey of stakeholders’
HPV-related projects, 3) assessment of current University of Wis-
consin–Madison research on HPV, and 4) evaluation of a quality
improvement education series for health care providers. The ob-
jective of this study was to assess local interventions to increase
HPV vaccination and organizational capacity for future collaborat-
ive work in Wisconsin.
Methods
Study population
We conducted a cross-sectional online survey of 277 Wisconsin
stakeholders in HPV vaccination activities from April 30, 2015,
through  June  30,  2015  (Appendix).  Stakeholders  were  public
health professionals, health care providers, educators, quality im-
provement professionals, researchers, and advocates from the state
who attended or  were  invited  to  the  Wisconsin  HPV Vaccine
Summit in June of 2014. The summit was a conference designed
to mobilize vaccine advocates by providing data on state-specific
HPV disease epidemiology and immunization rates, updates on the
diseases caused by HPV, vaccine safety information, and discus-
sions on how to address vaccination hesitancy and strengthen vac-
cination recommendations. We also surveyed members of the 15
local or regional immunization coalitions in Wisconsin. Stake-
holders received an email inviting them to participate in the on-
line survey. Four follow-up email reminders were sent to incom-
plete survey respondents and nonrespondents at intervals of every
2 weeks to encourage participation.
Measures
Study participants reported on their role in their organization and
answered other organization-related questions, including type of
organization, whether the organization belonged to a local or re-
gional immunization coalition, whether the organization accessed
the Wisconsin Immunization Registry, and whether the organiza-
tion used the Registry for Effectively Communicating Immuniza-
tion Needs and an electronic health record to track immunizations.
Respondents were also asked about their organization’s interest in
conducting new activities and their capacity to take on new activit-
ies to promote HPV vaccination.
Respondents were asked whether their organizations conducted
any activities in Wisconsin in 2013, 2014, or 2015 related to HPV
vaccination. The activities were classified into 4 categories:1) ad-
olescents and their parents, 2) clinical and health care profession-
als, 3) communities and health systems, and 4) advocacy and pub-
lic policy. If respondents reported activities in any year in any of
these categories, they were asked to provide information about
how often they encountered certain barriers (never, rarely, some-
times, often, or always). The selections of sometimes, often, and
always were defined as barriers. In addition, respondents provided
information on their funding sources and collaborating organiza-
tions for each category of activities.
Statistical analysis
We calculated simple descriptive statistics to examine the preval-
ence of HPV vaccination-related activities that stakeholders con-
ducted from 2013 through 2015 and the barriers they encountered.
We then tested for trends in different activities over time. All ana-
lyses were performed with Stata/MP version 13.1 (StataCorp LP).
Significance was set at P less than .05.
Results
Of the 277 stakeholders we invited to participate, 117 replied, a re-
sponse rate of 42.2%. Of the 117 stakeholders who participated in
the survey, 37 (31.6%) classified themselves as public health pro-
fessionals, 21 (17.9%) as health care providers, and 9 (7.7%) as
educators (Table). Thirty (25.6%) of the respondents worked for
local public health departments, 8 (6.8%) worked for state health
departments, and 22 (18.8%) for health care providers/health sys-
tems (categories were not mutually exclusive). Fifty-six (47.9%)
indicated that they or their organization belonged to a local or re-
gional immunization coalition, 71 (60.7%) reported that their or-
ganizations currently accessed the Wisconsin Immunization Re-
gistry, 6 (5.1%) used the Regional Early Childhood Immunization
Network, and 32 (27.4%) used an electronic health record to track
immunizations. Over half of respondents 67 (57.3%) expressed a
medium to high level of interest in conducting new activities to
promote HPV vaccination. However, only 46 (39.3%) rated their
capacity to take on new activities as adequate (medium or high ca-
pacity).
Stakeholders reported on activities that their organizations conduc-
ted  in  recent  years  to  increase  HPV vaccination.  Ninety-four
(80.3%) reported that their organizations were involved in activit-
ies focusing on adolescents (girls or boys aged 11–18 y) and their
parents. In 2015, the most common activities involving adoles-
cents and their parents were providing printed educational materi-
als (69.2%), one-on-one consultations to adolescents and parents
on HPV vaccination (54.7%), reminders to adolescents and par-
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ents of when adolescents were due for HPV vaccination (47.9%),
and referrals to HPV vaccination services (46.2%). The pattern
was similar for 2013 and 2014, and the prevalence of these 4 types
of activities increased significantly over time (P < .05) (Figure 1a).
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Figures 1a–d. Percentage of Wisconsin stakeholder organizations (N = 117)
reporting  activities  to  increase  human  papillomavirus  vaccination  in
Wisconsin,  2013–2015.  Figure 1a shows stakeholder  organizations with
activities  focused  on  adolescents  and  parents,  1b  shows  stakeholder
organizations with activities focused on clinical and health professionals, 1c
shows stakeholder organizations with activities focused on communities and
health  systems,  and  1d  shows  stakeholder  organizations  with  activities
focused on advocacy and public policy. The rates of advocating for public
policy change and advocating for increased public funding increased over time
(P < .05).
 
Overall, 75 respondents reported barriers to activities focusing on
adolescents and parents. The most common barriers were lack of
education or understanding about HPV infection, including its link
to cancer (86.6%); logistical or other barriers to returning for the
full series of 3 shots (74.7%); requests that HPV vaccination be
deferred (71.7%); belief that the adolescent is not at risk for HPV
infection (71.6%); and the parent’s belief that child is too young
for the HPV vaccine (68.5%, Figure 2).
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Figures 2a–d. Percentage of Wisconsin stakeholder organizations (N = 117)
reporting barriers to human papillomavirus (HPV) vaccination, from 2013
through 2015.  Figure 2a shows percentage of  stakeholder  organizations
reporting barriers related to adolescents and parents (n = 75), 2b shows the
percentage of stakeholder organizations reporting barriers related to clinical
and health professionals (n = 54), 2c shows the percentage of stakeholder
organizations reporting barriers related to communities and health systems (n
= 43), and 2d shows the percentage of stakeholder organizations reporting
barriers related to advocacy and public policy (n = 10).  Abbreviation: STI,
sexually transmitted infection.
 
Seventy-six of the 117 respondents (65.0%) indicated that their or-
ganizations were conducting activities focusing on clinical and
health professionals to increase HPV vaccination. The most com-
monly reported activities in 2015 were providing printed educa-
tional materials (53.0% of stakeholders), professional education on
HPV vaccination (47.0%), protocols to track and report on HPV
vaccination rates (35.0%), and websites focused on health profes-
sionals (11.1%) (Figure 1b). The increase in all activity rates from
2013 to 2015 was significant (P < .05). Barriers most often en-
countered by these organizations (N = 54) were difficulty ensur-
ing that patients completed the 3-dose HPV vaccination series
(63.0%), concern that parents would decline HPV vaccination des-
pite appropriate counseling (57.7%), reluctance to discuss sexual-
ity or sexually transmitted infections (45.3%), concern about the
time it takes to discuss HPV vaccination with patients or parents
(41.5%),  and  HPV vaccination  not  being  required  by  schools
(37.1%) (Figure 2b).
Sixty-one stakeholders  (52.1%) identified their  organization’s
activities as projects focusing on communities and health systems.
The most commonly reported activity in this category in 2015 was
media campaigns to raise awareness about the need for HPV vac-
cination of adolescents (39.3%,), followed by community commit-
tee or work groups that focus on HPV vaccination (24.8%), sup-
port  for community groups that  fund and promote the vaccine
(23.1%), and community events or health fairs to promote HPV
vaccination (21.4%) (Figure 1c). The increase from 2013 through
2015 in these activities was significant (P < .05). Barriers experi-
enced in implementing community- and health-system–focused
activities (N = 43) were lack of education or understanding about
HPV infection, including its link to cancer (44.1%); difficulty en-
suring that patients will  complete the 3-dose HPV vaccination
series (41.9%); belief that younger adolescents are too young for
the HPV vaccinations (41.8%); and reluctance to discuss sexual-
ity or sexually transmitted infections (38.7%) (Figure 2c).
Lastly, 18 respondents (15.4%) indicated that they were involved
in activities focused on advocacy and public policy with the most
commonly reported activity in 2015 being efforts to increase HPV
vaccination rates through advocating public policy change (17 re-
spondents), followed by advocating for increasing public funding
for  HPV vaccination  (13  respondents)  and  advocating  for  in-
creased public funding for HPV research (5 respondents) (categor-
ies were not mutually exclusive). The rates of the former 2 activit-
ies increased over time (P < .05) (Figure 1d). Barriers to these
activities that respondents (N = 10) reported were described as
lack of provider recommendations for  HPV vaccination (7 re-
spondents), concerns about vaccine safety (6 respondents), and re-
luctance to discuss sexuality or sexually transmitted infections (6
respondents) (Figure 2d)
Most organizations reported working with partners on activities
promoting HPV vaccination: activities that focused on adoles-
cents and parents (50 of 94 respondents), activities that focused on
clinical and health professionals (47 of 76 respondents), activities
that  focused on communities and health systems (37 of 61 re-
spondents), and activities that focused on advocacy and public
policy (14 of 18 respondents). Commonly reported collaborators
were the Centers for Disease Control and Prevention (CDC), the
Wisconsin Immunization Program, local health departments, local
clinics and hospitals, schools, local immunization coalitions, the
Wisconsin Comprehensive Cancer Control Program, and the Wis-
consin chapter of the American Academy of Pediatrics. Primary
sources of funding for HPV vaccination activities were CDC, the
Wisconsin chapter of the American Academy of Pediatrics, the
Wisconsin Department of Health Services, the University of Wis-
consin Partnership Program, the Wisconsin Immunization Pro-
gram, immunization coalitions,  the Wisconsin Comprehensive
Cancer Control Program, and tax levy funds.
Discussion
Persistent HPV infection can lead to cancer of the cervix, vulva,
vagina, penis, anus, and oropharynx (12). The HPV vaccine is safe
and  effective  and  has  been  recommended  since  2006  (13).
However, HPV vaccination coverage has remained far below that
of other vaccinations administered to adolescents, in Wisconsin
and throughout the United States. To assess efforts to increase
HPV vaccination in Wisconsin and barriers encountered, we con-
ducted a survey of stakeholders involved in the effort. Findings
from the survey illustrate the HPV vaccination-related projects be-
ing conducted in Wisconsin and provide a roadmap for future col-
laboration and activities to increase HPV vaccination.Our survey
of stakeholder activities found that ongoing work is focused on 4
main groups: adolescents and parents, clinical and health profes-
sionals,  communities and health systems, and stakeholders in-
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volved with advocacy and public policy. HPV vaccination promo-
tion activities increased across all these groups from 2013 through
2015. Many survey respondents reported conducting activities that
were focused on adolescents and parents, the most common of
which were the provision of educational materials, one-on-one
consultations and referrals, and reminders for vaccination. The
main activities used to influence clinical and health professionals
were provision of educational materials, professional education,
and protocols to track and report vaccination rates. These activit-
ies are in line with research, which indicates that educational cam-
paigns directed at health care professionals and parents are key fa-
cilitators for promoting HPV vaccination (14). Examples of educa-
tional efforts to raise awareness about HPV and HPV vaccination
are media campaigns, printed materials, online information, we-
binars, conferences, and in-person training sessions. Of the activit-
ies  designed to affect  communities  and health systems,  media
campaigns to raise awareness were used most often, followed by
health fairs and community group collaborations. We identified
fewer activities in the area of advocacy and public policy, but
among the activities reported were advocating for public policy
change and advocating for increased public funding for vaccina-
tion. HPV vaccination promotion activities in Wisconsin are simil-
ar to efforts conducted at the health care practice or community
level in other parts of the United States. The effectiveness of inter-
ventions to increase HPV vaccination has varied, and further re-
search is needed (15–17).
As in other  research,  Wisconsin stakeholders  reported several
main barriers to vaccination across groups: lack of understanding
about HPV and its link to cancer, reluctance to discuss sexuality,
parental resistance to the vaccination, belief that the adolescent is
too young or is not at risk, difficulty with completion of the 3-dose
vaccine series, safety concerns, and concern about promoting risky
sexual behavior (3,18,19). Health care providers have been identi-
fied as uniquely positioned to address barriers perceived by par-
ents. They can initiate conversations to address concerns and mis-
understandings and recommend the vaccine (19). Studies have
shown that parents and patients want additional information about
HPV and the HPV vaccine and that  they trust  the information
provided by health care providers (20). Providers need additional
training on how to give a strong, clear recommendation and com-
municate the urgency and importance of HPV vaccination (14).
Other potential strategies for providers and health care systems to
increase HPV vaccination rates are reducing missed clinical op-
portunities and administering the HPV vaccine at the same time as
other adolescent vaccines (18). To reduce the number of HPV-re-
lated cancer deaths in Wisconsin and reach the Healthy People
2020 goal of 80% HPV vaccination coverage, continued efforts
are needed to cultivate provider champions for the vaccine, edu-
cate the public about its safety and efficacy, increase access to
vaccination, and reduce missed clinical opportunities to vaccinate
(21). The consistency of barriers cited across target groups related
to the lack of understanding about HPV, the HPV vaccine, and
HPV related cancers indicates that future efforts should focus on
enhanced education and communication strategies for providers,
parents, adolescents, and communities. The Advisory Committee
on Immunization Practices recommends that young adolescents
(aged  9–14  y)  move  from a  3-dose  to  a  2-dose  HPV vaccine
schedule (22,23). This change presents new opportunities for in-
creasing adherence. The change, also recommended by CDC, was
based on a review of clinical trials showing that 2 doses of the
vaccine among young adolescents produced an immune response
similar  to,  or  higher  than,  the  response  in  young adults  (aged
16–26 y) who received 3 doses (22). Because survey respondents
cited logistical challenges to returning for the series of 3 shots as a
barrier, the move to a 2-dose schedule — which still provides safe,
long lasting, effective protection — may increase acceptance and
improve vaccination rates among young adolescents (23). More
than half of survey respondents expressed interest in conducting
new activities to promote HPV vaccination. However, because
less than 40% said they had the organizational capacity to do so,
policy efforts should focus on increasing funding for HPV vaccin-
ation education and promotion. HPV vaccination rates in Wiscon-
sin have increased in recent years. In 2015, the overall vaccina-
tion rate for adolescents aged 13 to 18 years was 44%, and in 2016
the rate was 49% (https://www.dhs.wisconsin.gov/immunization/
data.htm).
A strength of our study is that it is the first statewide, comprehens-
ive review of HPV vaccination activities in Wisconsin. A limita-
tion is that our list of Wisconsin HPV vaccination stakeholders
may be incomplete, and we do not have information about HPV
vaccination-related activities conducted by stakeholders who were
not identified. However, the participant list was reviewed by rep-
resentatives of the Wisconsin Immunization Program, the Wiscon-
sin chapter of the American Academy of Pediatrics, and the Uni-
versity of Wisconsin Immunization Taskforce to identify missing
stakeholders engaged in current or recent HPV vaccination work
who were then added to the group. Another limitation is that the
survey response rate was moderate (42.2%), but it was within the
range  (40%–60%)  recommended  for  surveys  to  inform  key
policies and resource allocation (24). A comparison between sur-
vey respondents and nonrespondents indicated that the geographic
distribution was similar between the 2 groups, suggesting that the
survey findings were representative of the state.The Wisconsin
HPV stakeholder survey found that activities promoting HPV vac-
cination are wide-ranging and have increased over time across the
state. Future interventions should address identified barriers and
employ evidence-based strategies for increasing HPV vaccination
rates.
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Table
Table. Characteristics of HPV Vaccination Stakeholders and Their Organizations in Wisconsin (N = 117)
Characteristic No. (%)
Position or role in organizationa
Public health professional 37 (31.6)
Health care provider 21 (17.9)
Educator 9 (7.7)
Advocate 6 (5.1)
Member of a community-based organization 7 (6.0)
Researcher/academic staff 6 (5.1)
Other or unknown 51 (43.6)
Type of organizationa
Local public health department 30 (25.6)
State public health department 8 (6.8)
Health care provider/health system 22 (18.8)
College or university 11 (9.4)
Other or unknown 50 (42.7)
Belong to a local or regional immunization coalition 56 (47.9)
Currently access the Wisconsin Immunization Registry 71 (60.7)
Currently use the Regional Early Childhood Immunization Network to track immunizations 6 (5.1)
Currently use an electronic health record to track immunization 32 (27.4)
Interest level in conducting new activities to promote HPV vaccination
High 40 (34.2)
Medium 27 (23.1)
Low 8 (6.8)
No 3 (2.6)
Don’t know 39 (33.3)
Capacity to take on new activities to promote HPV vaccination
High 7 (6.0)
Medium 39 (33.3)
Low 24 (20.5)
No 3 (2.6)
Don’t know 44 (37.6)
Have at least one staff member serving as a lead for a project to increase HPV vaccination rates 55 (47.0)
Abbreviation: HPV, human papillomavirus.
a Categories are not mutually exclusive.
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Appendix. Stakeholder Survey
This appendix is available for download as a Microsoft Word document at
https://www.cdc.gov/pcd/issues/2017/docs/16_0610Appendix.docx. [DOCX – 33KB]
PREVENTING CHRONIC DISEASE VOLUME 14, E85
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY SEPTEMBER 2017
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
10       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2017/16_0610.htm
